{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T13:07:34Z","timestamp":1777468054241,"version":"3.51.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BD"],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:p>BACKGROUND: Tucatinib is a tyrosine kinase inhibitor currently used in salvage therapy for human epidermal growth factor receptor 2 (HER2)-positive breast and colorectal cancer. The use of tucatinib alone or in combination with ado-trastuzumab emtansine (T-DM1) in the treatment of advanced HER2-positive cancers is rapidly expanding. OBJECTIVE\/METHODS: We report the case of a 66-year-old female who presented to the dermatology clinic with a one-year history of widespread telangiectasias that began after initiation of combination chemotherapy with tucatinib and T-DM1 for metastatic HER2-positive invasive ductal carcinoma. RESULTS: The patient\u2019s lesions regressed upon cessation of combination therapy and reappeared in the setting of tucatinib re-initiation, with gradual improvement over the following four months following electrocautery to the affected regions. CONCLUSIONS: We postulate that telangiectasias may be a previously unreported dermatologic side effect of combination treatment with tucatinib and T-DM1. Electrocautery is a safe and effective procedure to reduce the appearance of telangiectasias and improve patient satisfaction during chemotherapy.<\/jats:p>","DOI":"10.3233\/bd-230053","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T13:56:42Z","timestamp":1712066202000},"page":"61-64","source":"Crossref","is-referenced-by-count":2,"title":["Telangiectasias induced by combination tucatinib and ado-trastuzumab emtansine in a patient with metastatic breast cancer"],"prefix":"10.1177","volume":"43","author":[{"given":"Gabriella F.","family":"Rodriguez","sequence":"first","affiliation":[{"name":", University of Miami, , , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj","family":"Shah","sequence":"additional","affiliation":[{"name":", University of Miami, , , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea D.","family":"Maderal","sequence":"additional","affiliation":[{"name":", University of Miami Miller School of Medicine, , , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/BD-230053_ref1","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1470-2045(18)30256-0","article-title":"Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: A non-randomized, open-label, phase 1b study","volume":"19","author":"Murthy","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.3233\/BD-230053_ref2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2019","journal-title":"N Engl J Med"},{"key":"10.3233\/BD-230053_ref3","doi-asserted-by":"crossref","unstructured":"Strickler J, Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial, Ann Oncol, 30, 2019.","DOI":"10.1093\/annonc\/mdz246.005"},{"key":"10.3233\/BD-230053_ref4","first-page":"361","article-title":"Treating advanced unresectable or metastatic HER2-positive breast cancer: A spotlight on tucatinib","volume":"13","author":"Ulrich","year":"2021","journal-title":"Breast Cancer: Targets and Therapy"},{"key":"10.3233\/BD-230053_ref5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/13543784.2022.2053107","article-title":"Tucatinib: An investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer","volume":"31","author":"Ahn","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"10.3233\/BD-230053_ref6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10549-014-3001-z","article-title":"Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: A case series","volume":"146","author":"Sibaud","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.3233\/BD-230053_ref7","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1177\/10781552211073878","article-title":"Ado-trastuzumab emtansine associated spider telangiectasia","volume":"28","author":"Gursoy","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"10.3233\/BD-230053_ref8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.chest.2015.09.008","article-title":"Telangiectasia and pulmonary arterial hypertension following treatment with trastuzumab emtansine: A case report","volume":"149","author":"Kwon","year":"2016","journal-title":"Chest"},{"key":"10.3233\/BD-230053_ref9","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1535-7163.MCT-19-0873","article-title":"Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models","volume":"19","author":"Kulukian","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.3233\/BD-230053_ref10","first-page":"39","article-title":"The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer","volume":"9","author":"Sirhan","year":"2022","journal-title":"Mil Med Res"},{"key":"10.3233\/BD-230053_ref11","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-16-1496","article-title":"Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2(+)-advanced solid tumors, with an expansion cohort in HER2(+) metastatic breast cancer (MBC)","volume":"23","author":"Moulder","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["Breast Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/BD-230053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:32:42Z","timestamp":1777383162000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/BD-230053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":11,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/bd-230053","relation":{},"ISSN":["0888-6008","1558-1551"],"issn-type":[{"value":"0888-6008","type":"print"},{"value":"1558-1551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}